methadone and Communicable Diseases studies

Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.
6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.

Communicable Diseases: An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.

Research Excerpts

Excerpt	Relevance	Reference
"To examine the long-term impact of methadone maintenance treatment (MMT) on mortality, re-incarceration and hepatitis C seroconversion in imprisoned male heroin users."	9.11	Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. ( Dolan, KA; Kaldor, J; Shearer, J; White, B; Wodak, AD; Zhou, J, 2005)
"Buprenorphine appears to have an acceptable safety profile for use during pregnancy."	5.16	Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. ( Baxter, JK; Coyle, MG; Heil, SH; Holbrook, AM; Jones, HE; Kaltenbach, K; Martin, PR; Stine, SM, 2012)
"To examine the long-term impact of methadone maintenance treatment (MMT) on mortality, re-incarceration and hepatitis C seroconversion in imprisoned male heroin users."	5.11	Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. ( Dolan, KA; Kaldor, J; Shearer, J; White, B; Wodak, AD; Zhou, J, 2005)

Research

Studies (9)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Child's Head Circumference Measurement (Measured at Birth)

Child's Length of Hospital Stay

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (22.22)	18.2507
2000's	4 (44.44)	29.6817
2010's	3 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Kazatchkine, M	1
Arends, MT	1
De Haan, HA	1
Van 't Hoff, GI	1
Burki, T	1
Holbrook, AM	1
Baxter, JK	1
Jones, HE	1
Heil, SH	1
Coyle, MG	1
Martin, PR	1
Stine, SM	1
Kaltenbach, K	1
Dolan, KA	1
Shearer, J	1
White, B	1
Zhou, J	1
Kaldor, J	1
Wodak, AD	1
Miller, CL	1
Strathdee, SA	1
Li, K	1
Kerr, T	1
Wood, E	1
Baumgarten, R	1
Stark, K	1
Müller, R	1
Clark, HW	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Maternal Opioid Treatment: Human Experimental Research[NCT00271219]	Phase 3	175 participants (Actual)	Interventional	2005-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	cm (Mean)
A Methadone	33.0
B Buprenorphine	33.8

(NCT00271219)
Timeframe: delivery until hospital discharge (min=2 days, max=79 days)

Child's Peak Daily Total NAS Score

Intervention	days (Mean)
A Methadone	17.5
B Buprenorphine	10.0

NAS was measured with the MOTHER NAS scale, which includes 28 items, 19 of which are used for scoring and medication decisions. Scores can range from 0 to 42, with higher scores indicating more severe withdrawal. (NCT00271219)
Timeframe: minimum twice daily from birth until NAS no longer measured (min=10 days)

Mother's HIV Risk Behaviors (Measured Monthly by Risk Behavior Assessment)

Intervention	Score on the scale (Mean)
A Methadone	12.8
B Buprenorphine	11.0

(NCT00271219)
Timeframe: monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)

Mother's Measures of Dose Adequacy and Acceptance Over Time (Measured Weekly by Dose Adequacy Measure)

Intervention	percentage of HIV risk behaviors (Number)
A Methadone	NA
B Buprenorphine	NA

Pregnant women maintained on an opioid agonist medication may require upward adjustment to their medication during the course of pregnant. The Dose Adequacy Measure represented a recordation of dosing adjustments during the course of the study. (NCT00271219)
Timeframe: from study entry until discontinuation or delivery (min=29 days, max=239 days)

Mother's Psychosocial Functioning at Delivery as Measured by the Addiction Severity Index Psychosocial Index Score

Intervention	dose increase per trimester (Number)
A Methadone	NA
B Buprenorphine	NA

The Addiction Severity Index is a structured clinical interview that assesses problem severity in 7 areas of functioning: alcohol use, drug use, medical, legal, employment, psychosocial, and psychiatric status. Each area of functioning yields a composite scale score between 0 and 1, with higher scores indicating greater problem severity in that area. Only the psychosocial index was examined in this study. (NCT00271219)
Timeframe: at delivery

Mother's Self-report of Drug Use (Measured Monthly by Time Line Follow Back)

Intervention	Score on the scale (Mean)
Methadone	.014
Buprenorphine	.088

(NCT00271219)
Timeframe: monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)

Number of Children Requiring Treatment for Neonatal Abstinence Signs (NAS)

Intervention	percentage of drug use (Number)
A Methadone	NA
B Buprenorphine	NA

Neonatal abstinence syndrome (NAS) characterized by hyperirritability of the central nervous system and dysfunction in the autonomic nervous system, gastrointestinal tract, and respiratory system.11 When left untreated, NAS can result in serious illness (e.g., diarrhea, feeding difficulties, weight loss, and seizures) and death. (NCT00271219)
Timeframe: From birth until hospital discharge (min=4 days, max=10, depending on site)

Total Amount of Morphine Sulfate That a Neonate Receives to Treat NAS

Intervention	participants (Number)
A Methadone	41
B Buprenorphine	27

Total amount in mg (NCT00271219)
Timeframe: Start of NAS treatment until discontinuation of NAS treatment (min=0 days, max=76 days)

Article	Year
Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction (Abingdon, England), 2012, Volume: 107 Suppl 1 Topics: Adolescent; Adult; Analgesics, Opioid; Analysis of Variance; Buprenorphine; Communicable Diseases; F	2012
Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction (Abingdon, England), 2005, Volume: 100, Issue:6 Topics: Adult; Cohort Studies; Communicable Diseases; Follow-Up Studies; Hepatitis C; Heroin Dependence; HIV	2005

Article	Year
First Dutch national guidelines--pharmacological care for detained opioid addicts. International journal of prisoner health, 2009, Volume: 5, Issue:4 Topics: Buprenorphine; Communicable Diseases; Comorbidity; Continuity of Patient Care; Female; Health Policy	2009
Russia's drug policy fuels infectious disease epidemics. The Lancet. Infectious diseases, 2012, Volume: 12, Issue:4 Topics: Communicable Diseases; Drug Users; Epidemics; Humans; Methadone; Needle-Exchange Programs; Public Po	2012
A longitudinal investigation into excess risk for blood-borne infection among young injection drug users (IUDs). The American journal of drug and alcohol abuse, 2007, Volume: 33, Issue:4 Topics: Adult; Age Factors; Amphetamine-Related Disorders; British Columbia; Cocaine-Related Disorders; Comm	2007
Correlation between disease and community: is drug addiction a problem of fringe groups? Forensic science international, 1993, Volume: 62, Issue:1-2 Topics: Communicable Disease Control; Communicable Diseases; Cost of Illness; Crime; Female; Germany; HIV Se	1993
HIV prevalence and risk behaviour in injecting drug users in Berlin. Forensic science international, 1993, Volume: 62, Issue:1-2 Topics: Adult; Age Factors; Berlin; Blood-Borne Pathogens; Communicable Diseases; Condoms; Cross-Sectional S	1993
A new era in opioid dependency treatment. Recent law allows qualified physicians to provide care in office setting. Postgraduate medicine, 2001, Volume: 109, Issue:6 Topics: Buprenorphine; Certification; Communicable Diseases; Family Practice; Humans; Information Services;	2001

methadone and Communicable Diseases